SEC Filing Summary: Prima BioMed Ltd (Form 6-K)
Business Context and Reporting Period
This Form 6-K was filed by Prima BioMed Ltd, a foreign private issuer, on January 9, 2014. The registrant is headquartered in Sydney, Australia, and files annual reports under Form 20-F. The filing serves to distribute a press release regarding a scheduled media interview rather than reporting financial results.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. No financial statements or quantitative metrics are included in this specific report.
Material Changes
No material changes to financial position or operations are reported in this document. The filing contains no comparative data versus prior periods.
Guidance, Outlook, and Management Commentary
The primary content of this filing is the announcement that CEO Matthew Lehman is scheduled to be interviewed on Clear Channel Business Talk Radio DFW 1190AM. There is no financial guidance, risk disclosure, or discussion of contingencies provided in this text.
Key Facts for Investor Verification
- The filing is a non-financial disclosure regarding a media appearance by the CEO.
- No financial performance data is contained within this specific Form 6-K.
- Investors should refer to the company's most recent Form 20-F or quarterly reports for financial metrics.
- The company is listed as Prima BioMed Ltd, though the metadata request referenced "IMMUTEP Ltd"; the filing explicitly names Prima BioMed Ltd.